China / Hong Kong Company Update Inner Mongolia Yili Industrial

Bloomberg: 600887 CH Equity | Reuters: 600887.SS

Refer to important disclosures at the end of this report

DBS Group Research . Equity

1 Sep 2022

Investment Thesis

Firm market position

BUY

Last Traded Price (31 Aug 2022): RMB35.74 (CSI300 Index : 4,079) Price Target 12-mth: RMB46.00 (29% upside) (Prev RMB52.90) Analysts

Alison Fok +852 36684170 alisonfok@dbs.com Mavis Hui +852 36684188 mavis_hui@dbs.com Alice Hui +852 36684182 alicehuism@dbs.com

What's New

- 2Q22 earnings growth of 5% broadly in line with market expectations due to impact from lockdowns; 1H22 earnings rose 15% y-o-y
- Expect gradual demand recovery in 2H22 to sustain, with strong drivers coming from milk powder, cheese, and butter
- Trim FY22E/FY23E forecasts by 4%/1.5%; reiterate BUY, TP trimmed to Rmb46



Forecasts and Valuation

FULELASIS allu valuali				
FY Dec (RMBm) Turnover EBITDA Pre-tax Profit Net Profit Net Profit (Pre Ex) (core profit) Net Profit Gth (Pre-ex) (%) EPS (RMB)	2021A 110,144 11,702 10,112 8,759 8,759 8,759 23.0 1.44	2022F 126,355 13,431 11,735 9,907 9,907 13.1 1.62	2023F 142.608 16,719 13,379 11,541 11,541 16.5 1.88	2024F 159,637 21,062 16,262 14,027 14,027 21.5 2.27
EPS Gth (%)	22.3	12.5	15.9	20.9
Diluted EPS (RMB)	1.43	1.60	1.87	2.26
DPS (RMB)	0.96	1.08	1.25	1.51
BV Per Share (RMB)	1.08	1.05	1.04	1.04
PE (X)	24.8	22.1	19.0	15.7
P/Cash Flow (X)	14.0	18.5	14.6	11.7
P/Free CF (X)	24.5	52.0	34.1	23.7
EV/EBITDA (X)	21.4	19.1	15.7	12.8
Net Div Yield (%)	2.7	3.0	3.5	4.2
P/Book Value (X)	33.1	34.2	34.3	34.5
Net Debt/Equity (X)	CASH	CASH	CASH	CASH
ROAE (%)	136.9	154.8	180.3	219.2
Earnings Rev (%):		(4)	(1.5)	New
Consensus EPS (RMB)		1.66	1.94	2.28
Other Broker Recs:		B:45	S:0	H:0

Source of all data on this page: Company, DBS Bank (Hong Kong) Limited ("DBS HK"), Thomson Reuters





an increase in the health proposition, and a rise in disposable income.

77% of FY21 revenue, comprising UHT milk, yogurt, milk

Liquid milk sales driven by UHT milk. Liquid milk accounts for

beverages, and more. We expect UHT white milk to remain

the key driver, supported by a rise in consumption per capita,

Infant formula propelled to 2nd place in terms of market

share. Competition in infant formula has been fierce, with the rapid changes in regulations. With the consolidation of Austnutria, we expect Yili's market share to propel it to being the second-largest domestic infant formula player in China, after Feihe.

Emerging categories see encouraging trends. Yili has been investing in developing new products such as pasteurised milk, cheese, and butter to capture the fast-growing trends in these categories. Despite limited contribution at this juncture, we expect these products to continue to enrich Yili's strong dairy portfolio in the medium term.

Valuation:

We trim our earnings by 4%/1.5% respectively with mild trim in sales growth and introduce FY24E forecasts. Our TP stood at Rmb46, pegged to a 24.7x FY23F PE, equivalent to its 5-year trading average (Previously 31.7x FY22 PE).

Where we differ:

We forecast earnings CAGR of 15% in FY21-24E.

Key Risks to Our View:

COVID-19 impacts, volatility in raw material prices, tougher competition, execution risks on M&As, and trade war.

At A Glance

Issued Capital (m shrs)	6,383
Mkt Cap (RMBm/US\$m)	228,128 / 33,108
Major Shareholders (%)	
Huhhot Investment Company Ltd.	8.4
Free Float (%)	91.6
3m Avg. Daily Val. (US\$m)	241.23
GICS Industry: Consumer Staples / Food	l, Beverage & Tobacco



WHAT'S NEW

1H22 results takeaways

Yili's net earnings growth slowed to 5%, landing at Rmb2,614m in 2Q22 (1Q22: +24%), broadly in line with expectations. Revenue rose 11.6% to Rmb32,300m. Excluding the inclusion of Austnutria starting from 2Q22, revenue rose 9% y-o-y. In 1H22, net earnings rose 15%, while revenue rose 12%. Gross profit margin expanded 1.67ppt to 33.7% in 1H22, thanks to product mix enhancements with a higher contribution from milk powder and cheese & butter. Selling expense ratio also recorded a slight increase of 0.3ppt to 3.85% due to prior investments in fast-growing segments including milk powder and cheese & butter, as well as higher investments in the Winter Olympics.

By product segment, liquid milk, milk powder and products, ice-cream, and other products sales changed by -4.5%, +83.5%, +29.4%, and +103%, respectively, in 2Q22. Of this, cheese & butter sales surged by 40%. Excluding the impact of Austnutria, milk powder sales rose 31.7% in 2Q22. In 1H22, liquid milk, milk powder, ice-cream, and other products sales increased by 1.1%, 58%, 31.7%, and 155%, respectively.

By market share, Yili liquid milk/infant milk powder/adult milk powder/cheese market shares edged up 0.1ppt/3.5ppt/1.3ppt/4.0ppt by end-June 22. Of this, organic dairy-related products, dairy-based nutrition, cheese snacks, and natural mineral water sales exceeded 20%. **Raw milk price expectation.** Raw milk prices recorded a slight decline in 1H22, due to the lockdowns that negatively impacted consumer demand. The company expects the raw milk price to see a slight increase in 2H22 as demand gradually recovers, with expectations of a mild decline for the full year. Due to a stable supply increase in the upstream industry, raw milk prices are likely to remain stable in the medium term.

The company noted its sales have seen a gradual recovery since July and that it targets to reach number four in terms of global market position in 2022E. We remain positive about the group's overall trajectory on the back of growing dairy spending per capita. We trim our earnings by 4%/1.5% respectively with mild trim in sales growth and introduce FY24E forecasts. We forecast FY21-24E earnings CAGR of 15%. Maintain BUY.

Company Background

Yili is one of the leading companies involved in the processing and manufacturing of milk products such as ice-cream, milk powder, sterilised milk, and fresh milk. The group generates the bulk of its revenue from the liquid milk segment (UHT milk, UHT yogurt). It is also a significant player in the milk powder category.

Interim Income Statement (RMBm)

FY Dec	1H2021	2H2021	1H2022	% chg yoy	% chg hoh
_				10.0	
Revenue	56,294	53,850	63,213	12.3	17.4
Cost of Goods Sold	(35,238)	(41,179)	(42,049)	19.3	2.1
Gross Profit	21,056	12,671	21,164	0.5	67.0
Other Oper. (Exp)/Inc	(14,705)	(8,821)	(14,079)	(4.3)	59.6
Operating Profit	6,351	3,850	7,085	11.6	84.0
Other Non Opg (Exp)/Inc	(92)	(26)	(226)	(145.6)	766.8
Associates & JV Inc	0	0	0	nm	nm
Net Interest (Exp)/Inc	36	(7)	240	565.9	nm
Exceptional Gain/(Loss)	0	0	0	nm	nm
Pre-tax Profit	6,295	3,817	7,099	12.8	86.0
Тах	(975)	(405)	(960)	(1.5)	136.8
Minority Interest	(2)	29	7	nm	(77.0)
Net Profit	5,318	3,441	6,146	15.6	78.6
Net profit bef Except.	5,318	3,441	6,146	15.6	78.6
EBITDA	7,045	4,658	7,244	2.8	55.5
Margins (%)					
Gross Margins	37.4	23.5	33.5		
Opg Profit Margins	11.3	7.2	11.2		
Net Profit Margins	9.4	6.4	9.7		

Source: Company, DBS HK

•

Income Statement (RMB m)

FY Dec	2020A	2021A	% chg_vov
Revenue	96,886	110,144	13.7
Cost of Goods Sold	(61,806)	(76,417)	23.6
Gross Profit	35,080	33,727	(3.9)
Other Opng (Exp)/Inc	(26,334)	(23,526)	(10.7)
Operating Profit	8,746	10,201	16.6
Other Non Opg (Exp)/Inc	(408)	(118)	71.1
Associates & JV Inc	0	0	nm
Net Interest (Exp)/Inc	(188)	29	nm
Exceptional Gain/(Loss)	0	0	nm
Pre-tax Profit	8,150	10,112	24.1
Тах	(1,051)	(1,380)	31.3
Minority Interest	21	27	30.6
Net Profit	7,120	8,759	23.0
Net Profit before Except.	7,120	8,759	23.0
EBITDA	9,829	11,702	19.1
Margins & Ratio			
Gross Margins (%)	36.2	30.6	
Opg Profit Margin (%)	9.0	9.3	
Net Profit Margin (%)	7.3	8.0	


Source: Company, DBS HK

Income Statement (RMB m)


FY Dec	2021A	2022F	% chg vov	
Revenue	110,144	126,355	14.7	
Cost of Goods Sold	(76,417)	(86,652)	13.4	
Gross Profit	33,727	39,703	17.7	
Other Opng (Exp)/Inc	(23,526)	(27,744)	17.9	
Operating Profit	10,201	11,959	17.2	
Other Non Opg (Exp)/Inc	(118)	(273)	(131.1)	
Associates & JV Inc	0	0	nm	
Net Interest (Exp)/Inc	29	49	68.6	
Exceptional Gain/(Loss)	0	0	nm	
Pre-tax Profit	10,112	11,735	16.0	
Tax	(1,380)	(1,878)	36.0	
Minority Interest	27	49	81.8	
Net Profit	8,759	9,907	13.1	
Net Profit before Except.	8,759	9,907	13.1	
EBITDA	11,702	13,431	14.8	
Margins & Ratio				
Gross Margins (%)	30.6	31.4		
Opg Profit Margin (%)	9.3	9.5		
Net Profit Margin (%)	8.0	7.8		

Source: Company, DBS HK

Historical PE and PB band



Source: Thomson Reuters, DBS HK



Segmental Breakdown (RMB m)

FY Dec	2020A	2021A	2022F	2023F	2024F
Revenues (RMB m)					
Liquid milk	76,123	84,911	92,672	102,958	114,386
Milk and milk products	12,885	16,209	22,806	27,504	31,788
Mixed feed	179	182	0	0	0
lcecream	6,158	7,161	9,145	10,362	11,626
Other	1,540	1,681	1,732	1,784	1,837
Total	96,886	110,144	126,355	142,608	159,637
Course: Company DPC UK					

Source: Company, DBS HK

Income Statement (RMB m)

FY Dec	2020A	2021A	2022F	2023F	2024F
Revenue	96,886	110,144	126,355	142,608	159,637
Cost of Goods Sold	(61,806)	(76,417)	(86,652)	(97,630)	(108,059)
Gross Profit	35,080	33,727	39,703	44,978	51,578
Other Opng (Exp)/Inc	(26,334)	(23,526)	(27,744)	(31,481)	(35,208)
Operating Profit	8,746	10,201	11,959	13,497	16,370
Other Non Opg (Exp)/Inc	(408)	(118)	(273)	(167)	(156)
Associates & JV Inc	0	0	0	0	0
Net Interest (Exp)/Inc	(188)	29	49	49	49
Dividend Income	0	0	0	0	0
Exceptional Gain/(Loss)	0	0	0	0	0
Pre-tax Profit	8,150	10,112	11,735	13,379	16,262
Тах	(1,051)	(1,380)	(1,878)	(1,873)	(2,277)
Minority Interest	21	27	49	35	42
Preference Dividend	0	0	0	0	C
Net Profit	7,120	8,759	9,907	11,541	14,027
Net Profit before Except.	7,120	8,759	9,907	11,541	14,027
EBITDA	9,829	11,702	13,431	16,719	21,062
Growth					
Revenue Gth (%)	7.4	13.7	14.7	12.9	11.9
EBITDA Gth (%)	1.7	19.1	14.8	24.5	26.0
Opg Profit Gth (%)	5.5	16.6	17.2	12.9	21.3
Net Profit Gth (%)	2.2	23.0	13.1	16.5	21.5
Margins & Ratio					
Gross Margins (%)	36.2	30.6	31.4	31.5	32.3
Opg Profit Margin (%)	9.0	9.3	9.5	9.5	10.3
Net Profit Margin (%)	7.3	8.0	7.8	8.1	8.8
ROAE (%)	117.0	136.9	154.8	180.3	219.2
ROA (%)	10.0	8.6	9.3	10.2	11.8
ROCE (%)	15.7	12.2	13.2	14.6	16.8
Div Payout Ratio (%)	74.6	65.0	66.5	66.7	66.7
Net Interest Cover (x)	46.5	NM	NM	NM	NM
Source: Company, DBS HK					

Interim Income Statement (RMB m)

FY Dec	1H2020	2H2020	1H2021	2H2021	1H2022
Revenue	47,344	49,542	56,294	53,850	63,213
Cost of Goods Sold	(29,275)	(32,530)	(35,238)	(41,179)	(42,049)
Gross Profit	18,069	17,011	21,056	12,671	21,164
Other Oper. (Exp)/Inc	(13,203)	(13,131)	(14,705)	(8,821)	(14,079)
Operating Profit	4,866	3,880	6,351	3,850	7,085
Other Non Opg (Exp)/Inc	(421)	13	(92)	(26)	(226)
Associates & JV Inc	0	0	0	0	0
Net Interest (Exp)/Inc	(84)	(104)	36	(7)	240
Exceptional Gain/(Loss)	0	0	0	0	0
Pre-tax Profit	4,361	3,788	6,295	3,817	7,099
Tax	(604)	(446)	(975)	(405)	(960)
Minority Interest	22	(1)	(2)	29	7



Net Profit	3,779	3,341	5,318	3,441	6,146
Net profit bef Except.	3,779	3,341	5,318	3,441	6,146
Growth					
Revenue Gth (%)	5.3	9.5	18.9	8.7	12.3
Opg Profit Gth (%)	10.6	(0.2)	30.5	(0.8)	11.6
Net Profit Gth (%)	(1.0)	6.0	40.7	3.0	15.6
Margins					
Gross Margins (%)	38.2	34.3	37.4	23.5	33.5
Opg Profit Margins (%)	10.3	7.8	11.3	7.2	11.2
Net Profit Margins (%)	8.0	6.7	9.4	6.4	9.7
Source: Company, DBS HK					



FY Dec	2020A	2021A	2022F	2023F	2024F
	- 10-	6 9 9 4			
Net Fixed Assets	5,425	6,231	12,102	17,316	22,103
Invts in Associates & JVs	6,532	8,025	7,925	7,825	7,725
Other LT Assets	30,817	37,551	37,451	37,351	37,251
Cash & ST Invts	11,695	31,742	29,460	28,303	28,354
Inventory	7,545	9,015	10,222	11,518	12,748
Debtors	1,759	2,107	2,418	2,729	3,054
Other Current Assets	7,381	7,290	7,494	7,712	7,919
Total Assets	71,154	101,962	107,073	112,754	119,156
CT D L	7.04.2	42.264	12161	42.064	12.001
ST Debt	7,812	13,264	13,164	13,064	12,964
Creditors	11,376	13,660	15,597	17,573	19,451
Other Current Liab	15,580	16,372	15,970	15,970	15,970
LT Debt	5,137	8,568	8,568	8,568	8,568
Other LT Liabilities	716	1,307	1,307	1,307	1,307
Shareholder's Equity	6,083	6,400	6,400	6,400	6,400
Minority Interests	24,450	42,391	46,066	49,871	54,496
Total Cap. & Liab.	71,154	101,962	107,073	112,754	119,156
Non-Cash Wkg. Capital	(10,271)	(11,619)	(11,434)	(11,585)	(11,699)
Net Cash/(Debt)	(10,271) (1,254)	9,910	7,728	6,671	6,822
Debtors Turn (avg days)	(1,234)	9,910 7.0	7.0	7.0	7.0
Creditors Turn (avg days)	68.8	66.7	7.0 67.0	68.1	7.0 68.8
Inventory Turn (avg days)	45.7	44.0	43.9	44.6	45.1
Asset Turnover (x)	45.7	44.0	45.9	44.0 1.3	45.1
Current Ratio (x)	0.8	1.1	1.2	1.5	1.5
Quick Ratio (x)	0.4	0.8	0.7	0.7	0.6
Net Debt/Equity (X)	0.0	CASH	CASH	CASH	CASH
Net Debt/Equity ex MI (X)	0.2	CASH	CASH	CASH	CASH
Capex to Debt (%)	50.2	30.4	35.0	39.8	44.7
Z-Score (X) Source: Company, DBS HK	NA	NA	NA	NA	NA

Cash Flow Statement (RMB m)

FY Dec	2020A	2021A	2022F	2023F	2024F
Pre-Tax Profit	8,150	10,112	11,735	13,379	16,262
Dep. & Amort.	1,491	1,619	1,745	3,389	4,849
Tax Paid	(1,051)	(1,380)	(1,878)	(1,873)	(2,277)
Assoc. & JV Inc/(loss)	0	0	0	0	0
(Pft)/ Loss on disposal of FAs	0	0	0	0	0
Chg in Wkg.Cap.	1,284	690	217	152	114
Other Operating CF	(21)	4,486	0	0	0
Net Operating CF	9,852	15,528	11,819	15,046	18,948
Capital Exp.(net)	(6,500)	(6,644)	(7,616)	(8,602)	(9,636)
Other Invts.(net)	(2,522)	(657)	100	100	100
Invts in Assoc. & JV	2	0	100	100	100
Div from Assoc & JV	0	0	0	0	0
Other Investing CF	(23)	(496)	0	0	0
Net Investing CF	(9,043)	(7,797)	(7,416)	(8,402)	(9,436)
Div Paid	(5,310)	(5,693)	(6,585)	(7,701)	(9,361)
Chg in Gross Debt	5,122	4,981	(100)	(100)	(100)
Capital Issues	0	0	0	0	0
Other Financing CF	(2,372)	10,143	(2,514)	(2,514)	(2,514)
Net Financing CF	(2,560)	9,431	(9,199)	(10,315)	(11,975)
Currency Adjustments	0	0	0	0	0
Chg in Cash	(1,752)	17,162	(4,796)	(3,671)	(2,463)
Opg CFPS (RMB)	1.42	2.44	1.90	2.42	3.05
Free CFPS (RMB)	0.55	1.46	0.69	1.05	1.51

Source: Company, DBS HK



Target Price & Ratings History



S.N	o. Date	Closing Price	12-mth Target Price	Rating
1:	2-Nov-21	RMB42.56	RMB52.00	Buy
2:	21-Jan-22	RMB40.06	RMB52.00	Buy
3:	9-Feb-22	RMB38.76	RMB52.00	Buy
4:	29-Apr-22	RMB38.06	RMB52.90	Buy

Source: DBS HK

Analyst: Alison Fok Mavis Hui

Alice Hui



DBS HK recommendations are based on an Absolute Total Return* Rating system, defined as follows:

STRONG BUY (>20% total return over the next 3 months, with identifiable share price catalysts within this time frame)

BUY (>15% total return over the next 12 months for small caps, >10% for large caps)

HOLD (-10% to +15% total return over the next 12 months for small caps, -10% to +10% for large caps)

FULLY VALUED (negative total return, i.e., > -10% over the next 12 months)

SELL (negative total return of > -20% over the next 3 months, with identifiable share price catalysts within this time frame)

*Share price appreciation + dividends

Completed Date: 1 Sep 2022 13:09:43 (HKT) Dissemination Date: 1 Sep 2022 14:54:58 (HKT)

Sources for all charts and tables are DBS HK unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER

This report is prepared by DBS Bank (Hong Kong) Limited ("DBS HK"). This report is solely intended for the clients of DBS Bank Ltd., DBS HK, DBS Vickers (Hong Kong) Limited ("DBSV HK"), and DBS Vickers Securities (Singapore) Pte Ltd. ("DBSVS"), its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBS HK.

The research set out in this report is based on information obtained from sources believed to be reliable, but we (which collectively refers to DBS Bank Ltd., DBS HK, DBSV HK, DBSVS, its respective connected and associated corporations, affiliates and their respective directors, officers, employees and agents (collectively, the "**DBS Group**") have not conducted due diligence on any of the companies, verified any information or sources or taken into account any other factors which we may consider to be relevant or appropriate in preparing the research. Accordingly, we do not make any representation or warranty as to the accuracy, completeness or correctness of the research set out in this report. Opinions expressed are subject to change without notice. This research is prepared for general circulation. Any recommendation contained in this document does not have regard to the specific investment objectives, financial situation and the particular needs of any specific addressee. This document is for the information of addressees only and is not to be taken in substitution for the exercise of judgement by addressees, who should obtain separate independent legal or financial advice. The DBS Group accepts no liability whatsoever for any direct, indirect and/or consequential loss (including any claims for loss of profit) arising from any use of and/or reliance upon this document and/or further communication given in relation to this document. This document is not to be construed as an offer or a solicitation of an offer to buy or sell any securities. The DBS Group, along with its affiliates and/or persons associated with any of them may from time to time have interests in the securities mentioned in this document. The DBS Group, may have positions in, and may effect transactions in securities mentioned herein and may also perform or seek to perform broking, investment banking and other banking services for these companies.

Any valuations, opinions, estimates, forecasts, ratings or risk assessments herein constitutes a judgment as of the date of this report, and there can be no assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments. The information in this document is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed, it may not contain all material information concerning the company (or companies) referred to in this report and the DBS Group is under no obligation to update the information in this report.

This publication has not been reviewed or authorized by any regulatory authority in Singapore, Hong Kong or elsewhere. There is no planned schedule or frequency for updating research publication relating to any issuer.

The valuations, opinions, estimates, forecasts, ratings or risk assessments described in this report were based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. It can be expected that one or more of the estimates on which the valuations, opinions, estimates, forecasts, ratings or risk assessments were based will not materialize or will vary significantly from actual results. Therefore, the inclusion of the valuations, opinions, estimates, forecasts, ratings or risk assessments were based will not materialize or will vary significantly from actual results. Therefore, the inclusion of the valuations, opinions, estimates, forecasts, ratings or risk assessments described herein IS NOT TO BE RELIED UPON as a representation and/or warranty by the DBS Group (and/or any persons associated with the aforesaid entities), that:

- (a) such valuations, opinions, estimates, forecasts, ratings or risk assessments or their underlying assumptions will be achieved, and
- (b) there is any assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments stated therein.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets. Any assumptions made in this report that refers to commodities, are for the purposes of making forecasts for the company (or companies) mentioned herein. They are not to be construed as recommendations to trade in the physical commodity or in the futures contract relating to the commodity referred to in this report.

DBS Vickers Securities (USA) Inc ("DBSVUSA"), a US-registered broker-dealer, does not have its own investment banking or research department, has not participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months and does not engage in market-making.



ANALYST CERTIFICATION

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible for the content of this research report, in part or in whole, certifies that he or his associate¹ does not serve as an officer of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the entity who is responsible for the management of the issuer or the new listing applicant) and the research analyst(s) primarily responsible for the content of this research report. The new listing applicant (which includes in the case of a real estate investment trust, an officer of the entity who is responsible for the management of the issuer or the new listing applicant) and the research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests² in relation to an issuer or a new listing applicant that the analyst reviews. DBS Group has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the DBS Group and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of DBS Group's compensation to any specific investment banking function of the DBS Group.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES

1. DBS Bank Ltd, DBS HK, DBSVS or their subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of 29 Aug 2022.

2. Compensation for investment banking services:

DBSVUSA does not have its own investment banking or research department, nor has it participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months. Any US persons wishing to obtain further information, including any clarification on disclosures in this disclaimer, or to effect a transaction in any security discussed in this document should contact DBSVUSA exclusively.

3. Disclosure of previous investment recommendation produced:

DBS Bank Ltd, DBSVS, DBS HK, their subsidiaries and/or other affiliates of DBSVUSA may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed on page 1 of this report to view previous investment recommendations published by DBS Bank Ltd, DBS HK, DBSVS, their subsidiaries and/or other affiliates of DBSVUSA in the preceding 12 months.

¹ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial interest is defined as interests that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.



RESTRICTIONS ON DISTRIBUTION

	DISTRIBUTION
General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is being distributed in Australia by DBS Bank Ltd, DBSVS or DBSV HK. DBS Bank Ltd holds Australian Financial Services Licence no. 475946.
	DBS Bank Ltd, DBSVS and DBSV HK are exempted from the requirement to hold an Australian Financial Services Licence under the Corporation Act 2001 ("CA") in respect of financial services provided to the recipients. Both DBS Bank Ltd and DBSVS are regulated by the Monetary Authority of Singapore under the laws of Singapore, and DBSV HK is regulated by the Hong Kong Securities and Futures Commission under the laws of Hong Kong, which differ from Australian laws.
	Distribution of this report is intended only for "wholesale investors" within the meaning of the CA.
Hong Kong	This report is being distributed in Hong Kong by DBS Bank Ltd, DBS Bank (Hong Kong) Limited and DBS Vickers (Hong Kong) Limited, all of which are registered with or licensed by the Hong Kong Securities and Futures Commission to carry out the regulated activity of advising on securities. DBS Bank Ltd., Hong Kong Branch is a limited liability company incorporated in Singapore.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is distributed in Malaysia by AllianceDBS Research Sdn Bhd ("ADBSR"). Recipients of this report, received from ADBSR are to contact the undersigned at 603-2604 3333 in respect of any matters arising from or in connection with this report. In addition to the General Disclosure/Disclaimer found at the preceding page, recipients of this report are advised that ADBSR (the preparer of this report), its holding company Alliance Investment Bank Berhad, their respective connected and associated corporations, affiliates, their directors, officers, employees, agents and parties related or associated with any of them may have positions in, and may effect transactions in the securities mentioned herein and may also perform or seek to perform broking, investment banking/corporate advisory and other services for the subject companies. They may also have received compensation and/or seek to obtain compensation for broking, investment banking/corporate advisory and other services from the subject companies.
Singapore	Wong Ming Tek, Executive Director, ADBSRThis report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 196800306E) or DBSVS (Company Regn No. 198600294G), both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, DBS Bank Ltd accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact DBS Bank Ltd at 6878 8888 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United	For any query regarding the materials herein, please contact [Chanpen Sirithanarattanakul] at [research@th.dbs.com]This report is produced by DBS HK which is regulated by the Hong Kong Monetary Authority
Kingdom	This report is disseminated in the United Kingdom by DBS Bank Ltd, London Branch ("DBS UK"). DBS Bank Ltd is regulated by the Monetary Authority of Singapore. DBS UK is authorised by the Prudential Regulation Authority and is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority.
	In respect of the United Kingdom, this report is solely intended for the clients of DBS UK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBS UK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments.



Dubai International Financial Centre	This communication is provided to you as a Professional Client or Market Counterparty as defined in the DFSA Rulebook Conduct of Business Module (the "COB Module"), and should not be relied upon or acted on by any person which does not meet the criteria to be classified as a Professional Client or Market Counterparty under the DFSA rules. This communication is from the branch of DBS Bank Ltd operating in the Dubai International Financial Centre (the "DIFC") under the trading name "DBS Bank Ltd. (DIFC Branch)" ("DBS DIFC"), registered with the DIFC Registrar of Companies under number 156 and having its registered office at units 608 - 610, 6th Floor, Gate Precinct Building 5, PO Box 506538, DIFC, Dubai, United Arab Emirates. DBS DIFC is regulated by the Dubai Financial Services Authority (the "DFSA") with a DFSA reference number F000164. For more information on DBS DIFC and its affiliates, please see <u>http://www.dbs.com/ae/our-network/default.page</u> . Where this communication contains a research report, this research report is prepared by the entity referred to therein, which may be DBS Bank Ltd or a third party, and is provided to you by DBS DIFC. The research report has not been reviewed or authorised by the DFSA. Such research report is distributed on the express understanding that, whilst the information contained within is believed to be reliable, the information has not been independently verified by DBS DIFC. Unless otherwise indicated, this communication does not constitute an "Offer of Securities to the Public" as defined under Article 12 of the Markets Law (DIFC Law No.1 of 2012) or an "Offer of a Unit of a Fund" as defined under Article 19(2) of the Collective Investment Law (DIFC Law No.2 of 2010). The DFSA has not responsibility for reviewing or verifying this communication or any associated documents in connection with this investment and it is not subject to any form of regulation or approval by the DFSA. Accordingly, the DFSA has not approved this communication reany associated documents, and has n
United States	This report was prepared by DBS HK. DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

DBS Bank (Hong Kong) Limited

13th Floor One Island East, 18 Westlands Road, Quarry Bay, Hong Kong Tel: (852) 3668-4181, Fax: (852) 2521-1812



DBS Regional Research Offices

HONG KONG DBS Bank (Hong Kong) Ltd Contact: Dennis Lam

13th Floor One Island East, 18 Westlands Road, Quarry Bay, Hong Kong Tel: 852 3668 4181 Fax: 852 2521 1812 e-mail: dbsvhk@dbs.com

SINGAPORE DBS Bank Ltd Contact: Paul Yong

12 Marina Boulevard, Marina Bay Financial Centre Tower 3 Singapore 018982 Tel: 65 6878 8888 e-mail: groupresearch@dbs.com Company Regn. No. 196800306E

INDONESIA

PT DBS Vickers Sekuritas (Indonesia) Contact: Maynard Priajaya Arif

DBS Bank Tower Ciputra World 1, 32/F Jl. Prof. Dr. Satrio Kav. 3-5 Jakarta 12940, Indonesia Tel: 62 21 3003 4900 Fax: 6221 3003 4943 e-mail: indonesiaresearch@dbs.com

THAILAND

DBS Vickers Securities (Thailand) Co Ltd Contact: Chanpen Sirithanarattanakul

989 Siam Piwat Tower Building, 9th, 14th-15th Floor Rama 1 Road, Pathumwan, Bangkok Thailand 10330 Tel. 66 2 857 7831 Fax: 66 2 658 1269 e-mail: research@th.dbs.com Company Regn. No 0105539127012 Securities and Exchange Commission, Thailand